Akute myeloische Leukämie beim alten und geriatrischen Patienten

Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die akute myeloische Leukämie (AML) ist häufigste akute Leukämie im Erwachsenenalter, wobei mehr als die Hälfte der Patienten zum Zeitpunkt der Diagnosestellung älter als 65 Jahre alt sind. Zu Beginn der Behandlung eines älteren AML-Patienten ist die Auswahl einer geeigneten Primärtherapie von entscheidender Bedeutung. Hierbei müssen neben dem Wunsch des Patienten auch patientenbezogene sowie krankheitsspezifische Faktoren berücksichtigt werden. Für die individuelle Prognoseabschätzung steht heute eine Vielzahl von Scores zur Verfügung, die für die Einschätzung des Patienten im Sinne eines geriatrischen Assessments sowie für die Risikobeurteilung der vorliegenden AML-Erkrankung Anwendung finden. Auch wenn die optimale Erstlinientherapie für ältere Patienten mit einer AML weiterhin unklar ist, profitieren prinzipiell auch ältere Patienten von einer intensiven Therapie, sofern sie sich hierfür eignen. Alternativ stehen nicht-intensive und rein supportive Therapieoptionen zur Verfügung.

Literatur

  1. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P (2005) Outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 19(2):230–233Google Scholar
  2. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH (2006) Age and acute myeloid leukemia. Blood 107(9):3481–3485.  https://doi.org/10.1182/blood-2005-09-3724CrossRefPubMedPubMedCentralGoogle Scholar
  3. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–237CrossRefPubMedGoogle Scholar
  4. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a cancer and leukemia group B study. J Clin Oncol 28(4):596–604.  https://doi.org/10.1200/JCO.2009.25.1496CrossRefPubMedGoogle Scholar
  5. Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F, Lo Coco F (2007) Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 92(9):1273–1274CrossRefPubMedGoogle Scholar
  6. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109(6):1114–1124.  https://doi.org/10.1002/cncr.22496CrossRefPubMedGoogle Scholar
  7. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D (2015a) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16(13):1295–1305.  https://doi.org/10.1016/S1470-2045(15)00193-X
  8. Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE (2015b) A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25):3878–3885.  https://doi.org/10.1182/blood-2015-01-623447
  9. Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerova K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C (2016) Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer.  https://doi.org/10.1002/cncr.30220PubMedGoogle Scholar
  10. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, Gonzalez M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Löwenberg B, Sanz MA (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111(7):3395–3402.  https://doi.org/10.1182/blood-2007-07-100669
  11. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474.  https://doi.org/10.1182/blood-2009-07-235358
  12. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30 % blasts. Blood 126(3):291–299.  https://doi.org/10.1182/blood-2015-01-621664
  13. Erba HP (2007) Prognostic factors in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program 420–428.  https://doi.org/10.1182/asheducation-2007.1.420
  14. Estey EH, Giles FJ, Beran M, O’Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM (2002) Experience with gemtuzumab ozogamycin („mylotarg“) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99(11):4222–4224.  https://doi.org/10.1182/blood-2001-12-0174CrossRefPubMedGoogle Scholar
  15. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25(14):1824–1831.  https://doi.org/10.1200/JCO.2007.10.6559CrossRefPubMedGoogle Scholar
  16. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569CrossRefPubMedGoogle Scholar
  17. Ferrara F, Palmieri S, Mele G (2004) Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 89(8):998–1008PubMedGoogle Scholar
  18. Fritsch S, Buske C, Wörmann B, Wedding U, Hiddemann W, Spiekermann K (2007) Therapy of acute myeloid leukemia (AML) for medically non-fit patients. Med Klin (Munich) 102(4):324–329.  https://doi.org/10.1007/s00063-007-1038-zCrossRefGoogle Scholar
  19. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624–627.  https://doi.org/10.1111/j.1365-2141.2006.06476.xCrossRefPubMedGoogle Scholar
  20. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM (2015) Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 33(31):3641–3649.  https://doi.org/10.1200/JCO.2014.60.0890
  21. Hemmati PG, Terwey TH, Na IK, Jehn CF, le Coutre P, Vuong LG, Dörken B, Arnold R (2015) Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. Eur J Haematol 95(6):498–506.  https://doi.org/10.1111/ejh.12522
  22. Hulegärdh E, Punab M, Holmberg E, Palk K, Laane E, Everaus H, Wennström L, Stockelberg D (2016) Acute de novo Leukemia in Estonia and Western Sweden 1982–2006: positive trend in the survival of acute leukemia over 25 years. Acta Haematol 136(3):167–173.  https://doi.org/10.1159/000446525
  23. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood 113(18):4179–4187.  https://doi.org/10.1182/blood-2008-07-172007CrossRefPubMedGoogle Scholar
  24. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670–2677.  https://doi.org/10.1200/JCO.2011.38.9429CrossRefPubMedPubMedCentralGoogle Scholar
  25. Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C (2010) Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376(9757):2000–2008.  https://doi.org/10.1016/S0140-6736(10)62105-8
  26. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Chiarella M, Louie AC, Medeiros BC (2016) Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary) AML. ASCO Meeting Abstracts 34(15_suppl):7000Google Scholar
  27. Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F (2011) GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol 154(5):564–568.  https://doi.org/10.1111/j.1365-2141.2011.08593.x
  28. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Derolf ÅR, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia 25(7):1128–1134.  https://doi.org/10.1038/leu.2011.78
  29. Lengfelder E, Hofmann WK, Nowak D (2012) Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 26(3):433–442.  https://doi.org/10.1038/leu.2011.245CrossRefPubMedGoogle Scholar
  30. Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T (2013a) Outcome of elderly patients with acute promyelocytic leukemia: results of the German acute myeloid leukemia cooperative group. Ann Hematol 92(1):41–52.  https://doi.org/10.1007/s00277-012-1597-9
  31. Lengfelder E, Hofmann WK, Nolte F (2013b) Management of elderly patients with acute promyelocytic leukemia: progress and problems. Ann Hematol 92(9):1181–1188.  https://doi.org/10.1007/s00277-013-1788-zCrossRefPubMedPubMedCentralGoogle Scholar
  32. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104(7):1995–1999.  https://doi.org/10.1182/blood-2004-04-1550CrossRefPubMedGoogle Scholar
  33. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–121.  https://doi.org/10.1056/NEJMoa1300874
  34. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S et al (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European organization for research and treatment of cancer leukemia group. J Clin Oncol 7(9):1268–1274CrossRefPubMedGoogle Scholar
  35. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361(13):1235–1248.  https://doi.org/10.1056/NEJMoa0901409
  36. Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H (2012) A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 97(3):393–401.  https://doi.org/10.3324/haematol.2011.048231CrossRefPubMedPubMedCentralGoogle Scholar
  37. Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, Gobbi M, Nobile F, Gallo E, Fanin R, Amadori S, Vignetti M, Fioritoni G, Ferrara F, Peta A, Giustolisi R, Broccia G, Petti MC, Lo-Coco F (2003) Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17(6):1085–1090Google Scholar
  38. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10. J Clin Oncol 27(32):5397–5403.  https://doi.org/10.1200/JCO.2008.20.6490CrossRefPubMedPubMedCentralGoogle Scholar
  39. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S (2010) Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28(11):1878–1887.  https://doi.org/10.1200/JCO.2009.25.4821CrossRefPubMedPubMedCentralGoogle Scholar
  40. Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V (2014) Benefit of allogeneic transplantation in patients age >/= 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. Biol Blood Marrow Transplant 20(4):474–479.  https://doi.org/10.1016/j.bbmt.2013.12.560CrossRefPubMedGoogle Scholar
  41. Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Daniel MT, Labarthe A, Maarek O, Cassinat B, Adés L, Baruchel A, Degos L, Azoulay E, Dombret H (2014) Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer 50(6):1159–1168.  https://doi.org/10.1016/j.ejca.2013.11.023CrossRefPubMedGoogle Scholar
  42. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS (2014) Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica 99(8):1373–1379.  https://doi.org/10.3324/haematol.2014.103655CrossRefPubMedPubMedCentralGoogle Scholar
  43. Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T (2012) Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci 103(11):1974–1978.  https://doi.org/10.1111/j.1349-7006.2012.02390.x
  44. Ossenkoppele G, Löwenberg B (2015) How I treat the older patient with acute myeloid leukemia. Blood 125(5):767–774.  https://doi.org/10.1182/blood-2014-08-551499CrossRefPubMedGoogle Scholar
  45. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D’Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol 35(6):605–612.  https://doi.org/10.1200/JCO.2016.67.1982CrossRefPubMedGoogle Scholar
  46. Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M (2016) Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). Bone Marrow Transplant.  https://doi.org/10.1038/bmt.2016.156PubMedGoogle Scholar
  47. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96(4):1247–1253PubMedGoogle Scholar
  48. Sanz MA, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, Arias J, Deben G, Novo A, Bergua J, de la Serna J, Bueno J, Negri S, Beltran de Heredia JM, Martin G (2004) All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 104(12):3490–3493.  https://doi.org/10.1182/blood-2004-04-1642CrossRefPubMedGoogle Scholar
  49. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113(9):1875–1891.  https://doi.org/10.1182/blood-2008-04-150250
  50. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092–1099.  https://doi.org/10.1182/blood-2005-10-4165CrossRefPubMedGoogle Scholar
  51. Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA (2013) Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Ann Hematol 92(10):1389–1395.  https://doi.org/10.1007/s00277-013-1774-5CrossRefPubMedGoogle Scholar
  52. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD (2010) BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Blood 116(25):5660–5669.  https://doi.org/10.1182/blood-2010-06-290536CrossRefPubMedPubMedCentralGoogle Scholar
  53. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919.  https://doi.org/10.1182/blood-2005-05-2004CrossRefPubMedPubMedCentralGoogle Scholar
  54. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE (2014) Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 32(29):3249–3256.  https://doi.org/10.1200/JCO.2013.53.8157CrossRefPubMedPubMedCentralGoogle Scholar
  55. Swerdlow SH, Campo E, Harris NL, Jaffe, ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.Google Scholar
  56. Tsai CH, Hou HA, Tang JL, Liu CY, Lin CC, Chou WC, Tseng MH, Chiang YC, Kuo YY, Liu MC, Liu CW, Lin LI, Tsay W, Yao M, Li CC, Huang SY, Ko BS, Hsu SC, Chen CY, Lin CT, Wu SJ, Tien HF (2016) Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia 30(7):1485–1492.  https://doi.org/10.1038/leu.2016.65CrossRefPubMedGoogle Scholar
  57. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111(5):2505–2515.  https://doi.org/10.1182/blood-2007-07-102798CrossRefPubMedGoogle Scholar
  58. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrozek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD (2010) FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Blood 116(18):3622–3626.  https://doi.org/10.1182/blood-2010-05-283648CrossRefPubMedPubMedCentralGoogle Scholar
  59. Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, Hu L, Wang S, Zhao Y, Li X, Zhang Y, Fan S, Lv C, Li Y, Su Y, Zhao H, Zhang X, Zhou J (2013) Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 119(1):115–125.  https://doi.org/10.1002/cncr.27650CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Klinik 3Klinikum LeverkusenLeverkusenDeutschland
  2. 2.III. Medizinische KlinikUniversitätsmedizin MannheimMannheimDeutschland
  3. 3.Center for Cell and Gene TherapyBaylor College of MedicineTexasUSA

Section editors and affiliations

  • Ulrich Wedding
    • 1
  1. 1.Abteilung für PalliativmedizinUniversitätsklinikum Jena, Klinik für Innere Medizin IIJenaDeutschland

Personalised recommendations